This trial is evaluating whether ALLY will improve 1 primary outcome and 1 secondary outcome in patients with Suicidal Ideation. Measurement will happen over the course of 3 months.
This trial requires 1000 total participants across 2 different treatment groups
This trial involves 2 different treatments. ALLY is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
"Even though suicidal ideation is a very prevalent entity, suicidal ideas and behaviours are extremely rare in suicidal individuals. These behaviours can be treated, prevented, or prevented by targeting the underlying factors." - Anonymous Online Contributor
"Some signs of suicidal ideation include an increased desire for attention, difficulty in initiating plans, and feeling like it is no longer worthwhile to live. These five indicators were highly sensitive and specific for suicidal ideation in this population." - Anonymous Online Contributor
"It is difficult to draw a firm conclusion in this small study. There is a risk that, in contrast to the general population, these subjects are prone to succumb to adverse effects of antidepressants." - Anonymous Online Contributor
"About 100,000 people who seek medical attention every year in the Unites States are hospitalized or require care in one of the Departments of Psychiatry." - Anonymous Online Contributor
"While it would be too simplistic to attribute each case of suicidal ideation to one cause, there seems to be a significant degree to which certain types of stress or event can trigger suicidal thinking. For the most part, however, there appears to be a complicated interplay of factors which must be taken into account before a psychiatric diagnosis is placed on a suicidal individual." - Anonymous Online Contributor
"Cognitive behavioral therapy and psychological support in combination with medication is most effective for treating suicidal ideation. There is a lack of high quality, well designed randomized controlled trials to support the evidence base for antidepressant use. Randomized control trials to test CBT for depression and psychological treatments for anxiety may prove very useful to test the efficacy of treatment for suicidal ideation." - Anonymous Online Contributor
"Results from this meta-analysis do not corroborate the conclusions regarding suicidal ideation that are reported in literature. In addition, we found strong evidence that the effect size of depressive disorders on suicidal ideation is considerably smaller than is reported in literature, and it is likely underestimating the true effect size. Finally, while there is insufficient evidence on the effect of treatments for depression on suicidal ideation, the findings of this meta-analysis suggest that we would need to implement evidence-based therapies against depression for improving suicidal ideation." - Anonymous Online Contributor
"Ally significantly improved depressive symptoms in community pharmacy patients with suicidal ideation. Ally was well tolerated by these patients, who indicated that it is a valuable resource for treatment." - Anonymous Online Contributor
"Ally does not treat suicidal ideation itself. Ally does treat the suicidal thoughts and/or the plan; in nearly 90% cases the plan is completed. Ally doesn't treat, specifically, the actions which would cause or enhance the suicidal ideation. Ally treats the client who is suicidal and Ally helps the client deal with how he or she feels about the suicidal thoughts because Ally sees the client as being more responsible for his or her own feelings. Ally treats the client who is suicidal and Ally helps the client to manage. Ally does not address all the possible issues the client might have with suicidal ideation." - Anonymous Online Contributor
"Ally shows few adverse drug reactions if used according to the prescribing information provided and in compliance with the current prescribing information, manufacturer's instructions, and patient instructions. Ally causes little discomfort to participants and the study group, with few or no adverse drug reactions recorded, including: dizziness, headache, fatigue, nausea, and tiredness. Ally is well tolerated, with no reported suicidal ideation, suicidal behavior, or suicide attempts when used according to the prescriber's instructions. Ally appears to be safer to use than other antidepressants. Ally is a valuable medication that works and is well tolerated. Ally works to treat depression. Ally has a long-term therapeutic effect which is not predicted by response to acute therapy. Ally is not addictive." - Anonymous Online Contributor
"Ally is superior to a placebo. Ally may be an alternative treatment for patients with suicidal ideation who are not satisfied with their current therapy." - Anonymous Online Contributor
"We conclude that this patient has benefitted from the participation of other medical oncologists. Such participation is essential in the current healthcare environment in order to improve the prognosis of patients with multiple myeloma." - Anonymous Online Contributor